Edwards Lifesciences CorporationEW

Where EW's Net Debt / EBITDA sits inside its own 10-year distribution, with the yearly high, low and average.

$84.37-2.40 (-2.77%)Previous close
NYSEHealthcare

EW Net Debt / EBITDA: current value, 10-year range and year-by-year history

Net Debt / EBITDA History

Historically priceyAbove avgAround avgBelow avgHistorically cheap
EW Net Debt / EBITDA historyEW Net Debt / EBITDA from Sep 2023 to Jun 2026: low -1.78, high -0.28, latest -1.43.-1.9-1.47-1.03-0.6-0.16Sep 23Mar 24Sep 24Jun 25Dec 25Jun 26med -1.34

EW Net Debt / EBITDA by year

Yearly range of EW’s net debt / ebitda from 2016 to 2026. Over the full period it ranged from -1.8 to 0.5, averaging -0.4.

EW Net Debt / EBITDA — yearly low, average, high and year-end values
YearLowAverageHighYear-end
2026-1.4-1.3-1.2-1.4
2025-1.6-1.4-1.1-1.6
2024-1.8-1.0-0.3-1.3
2023-0.4-0.3-0.1-0.3
2022-0.3-0.2-0.0-0.0
2021-0.4-0.3-0.1-0.1
2020-0.5-0.30.0-0.5
2019-0.5-0.3-0.0-0.4
2018-0.2-0.1-0.0-0.1
20170.00.30.50.2
2016-0.1-0.1-0.1-0.1

Get notified when EW Net Debt / EBITDA crosses a threshold

Free — one alert setup, notifications by push, Telegram, or Discord.

How many years of operating earnings it would take to pay off the company's net debt. The most common leverage ratio — higher means more financial risk and less flexibility.

Formula(Total Debt − Cash) / EBITDA
Full guide
How to read this chart

Watch the trend more than the level. Declining ratio = deleveraging, growing financial flexibility. Rising ratio = increasing leverage, which constrains dividends, buybacks, and future investment.

Key caveats
  • Sector context is essential: 3× is aggressive for a consumer brand but normal for a regulated utility. Always compare to sector peers.
  • Large acquisitions spike the ratio temporarily — check whether the integration plan credibly drives paydown.
Pro — up to 30-year history

Unlock 10y, 15y, 20y, and 30y history with peer comparison and CSV export.